<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616601</url>
  </required_header>
  <id_info>
    <org_study_id>094-8251-301</org_study_id>
    <nct_id>NCT02616601</nct_id>
  </id_info>
  <brief_title>Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis</brief_title>
  <official_title>Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Fluorouracil 0.5% Cream to Carac Cream in Subjects With Actinic Keratoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil
      0.5% cream against the brand product (Carac) in subjects with actinic keratoses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind, vehicle-controlled, parallel group comparison study of a
      generic fluorouracil cream, 0.5% and Carac (fluorouracil) cream, 0.5% in subjects with
      actinic keratoses on the full face or balding scalp.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actinic Keratosis (AK) count</measure>
    <time_frame>6 week</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Carac Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carac (fluorouracil) 0.5% topical cream applied to the designated treatment area (full face or balding scalp) identified by the investigator once daily for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic Fluorouracil Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generic fluorouracil 0.5% topical cream applied to the designated treatment area (full face or balding scalp) identified by the investigator once daily for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream applied to the designated treatment area (full face or balding scalp) identified by the investigator once daily for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carac Cream</intervention_name>
    <description>Active drug product (brand) applied to face or scalp once daily for 2 weeks</description>
    <arm_group_label>Carac Cream</arm_group_label>
    <other_name>Fluorouracil, 5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic Fluorouracil Cream</intervention_name>
    <description>Active drug product (generic) applied to face or scalp once daily for 2 weeks</description>
    <arm_group_label>Generic Fluorouracil Cream</arm_group_label>
    <other_name>Florouracil, 5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Apply product to face or scalp once daily for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male and/or female, 18 years of age or older.

          -  Subject is willing and able to give written informed consent.

          -  Subject is willing and able to apply the test article(s) as directed, comply with
             study instructions and commit to all follow-up visits for the duration of the study.

          -  Subject has a clinical diagnosis of actinic keratoses with at least five and no more
             than ten clinically typical, visible or palpable, discrete, AK lesions, each at least
             4 mm in diameter on the face (excluding ears) or balding scalp.

          -  Subject is in good general health and free of any disease state or physical condition
             that might impair evaluation of AK lesions or which, in the investigator's opinion,
             exposes the subject to an unacceptable risk by study participation.

          -  Females must be post-menopausal, surgically sterile, or use an effective method of
             birth control with a negative urine pregnancy test (UPT) at the Baseline Visit

        Exclusion Criteria:

          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.

          -  Subject is currently enrolled in an investigational drug or device study.

          -  Subject has used an investigational drug or investigational device treatment within 30
             days prior to the Baseline Visit.

          -  Subject has hyperkeratotic, hypertrophic, or large mat-like AKs (e.g., AK &gt;1 cm2 in
             size) within the Treatment Area.

          -  Subject has the need or plans to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

          -  Subject is immunosuppressed (e.g., human immunodeficiency virus (HIV), systemic
             malignancy, graft host disease, etc.)

          -  Subject has experienced an unsuccessful outcome from previous topical fluorouracil
             therapy (an unsuccessful outcome is defined as after a reasonable therapeutic trial
             with no compliance issues and the topical drug did not work).

          -  Subject has a history of sensitivity to any of the ingredients in the test articles.

          -  Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.

          -  Subject used topical creams, lotions, or gels of any kind within the selected
             Treatment Area within one day prior to entry into the study.

          -  Subject has used topical medications; corticosteroids, alpha hydroxy acids (e.g.,
             glycolic acid, lactic acid, etc. &gt;5%), beta hydroxy acid (salicylic acid &gt;2%), urea
             &gt;5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, or prescription
             retinoids (e.g., tazarotene, adapalene, tretinoin) within the selected Treatment Area
             (face or balding scalp) within one (1) month prior to the Baseline Visit.

          -  Subject has had cryodestruction, curettage, photodynamic therapy, surgical excision,
             or other treatments for AK within the selected Treatment Area (face or balding scalp)
             within one (1) month prior to the Baseline Visit.

          -  Subject has used oral corticosteroid therapy, interferon, cytotoxic drugs,
             immunomodulators, immunosuppressive therapies, or retinoids within one month prior to
             the Baseline Visit.

          -  Subject has had dermatologic procedures or surgeries such as: laser resurfacing,
             Psoralen + ultraviolet A (PUVA) therapy, ultraviolet B therapy, chemical peels, or
             dermabrasion within the selected Treatment area (face or balding scalp) within six
             months prior to the Baseline Visit.

          -  Subject has lesions suspicious for skin cancer (skin cancer not ruled out by biopsy)
             or untreated skin cancers within the selected Treatment Area (face or balding scalp).

          -  Subject has any skin pathology or condition on the face or balding scalp that, in the
             investigator's opinion, could interfere with the evaluation of the test article or
             requires the use of interfering topical, systemic, or surgical therapy.

          -  Subject has any condition which, in the investigator's opinion, would make it unsafe
             or preclude the subject's ability to fully participate in this research study.

          -  Subject is unable to communicate or cooperate with the investigator due to language
             problems, poor mental development, impaired cerebral function, or physical
             limitations.

          -  Subject is known to be noncompliant or is unlikely to comply with the requirements of
             the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in
             the opinion of the investigator.

          -  Subject has been previously enrolled in the same study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Lau, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actavis Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SD Sports Medicine &amp; Family Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Assoc</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Dlazer</name>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Southben Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for research Corp</name>
      <address>
        <city>Clinton</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academis Dermatology Assoc</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Co.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

